Key result
Growth hormone replacement therapy in children with growth hormone deficiency reduced body fat percentage and atherogenic indices while increasing lean body mass, without altering glucose metabolism.
Why the study?
Does growth hormone replacement therapy improve health risk factors in patients with growth hormone deficiency?
Observational (n=40)
Does growth hormone replacement therapy improve health risk factors in patients with growth hormone deficiency?
Answers are grounded in this paper and cite their sources.
Growth hormone replacement therapy improves metabolic and atherogenic risk factors in GH-deficient patients without adversely affecting glucose metabolism.
Growth hormone (GH) is important in the regulation of fat, carbohydrate, and protein metabolism. These metabolic effects subsequently affect health risk factors, such as body composition, atherogenic risk factors, and glucose intolerance. GH deficiency is associated with obesity which reportedly responds to GH treatment. Children and adults with GH deficiency often have hypercholesterolemia and thus might be at increased risk of having atherosclerotic diseases in later life. In fact, adults with GH deficiency have been reported to have an increased mortality rate as a result of cardiovascular disease. On the other hand, the results of GH treatment in relation to carbohydrate metabolism are inconsistent in GH-deficient children. We evaluated the changes in health risk factors during GH replacement therapy in 40 children, 31 boys and 9 girls, with GH deficiency and compared our results with those in adult patients. In conclusion, GH replacement therapy in children and adults with GH deficiency can reduce health risk factors without altering glucose metabolism. These beneficial effects are reportedly reversed after the discontinuation of GH therapy. It therefore seems prudent to continue life-long GH replacement therapy in these patients.
No takes yet. Share an insight, caveat, or question.
Kohno et al. (1996) conducted an observational in Growth hormone deficiency (n=40). Growth hormone replacement therapy vs. Baseline was evaluated on Body composition (body fat percentage and lean body mass) and atherogenic indices. Growth hormone replacement therapy in children with growth hormone deficiency reduced body fat percentage and atherogenic indices while increasing lean body mass, without altering glucose metabolism.
Synapse has enriched 10 related papers. Consider them for comparative context: